At a glance
A secretagogue used to investigate ghrelin-receptor signaling.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source reports hormone-response experiments and broader body-composition discussions. A rise in GH or IGF-1 is a biomarker finding, not a complete assessment of benefit and risk.[1][5][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of GHRP-2.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 6 units (0.06 mL) |
| Weeks 3–4 | 150 mcg | 9 units (0.09 mL) |
| Weeks 5–8 | 200 mcg | 12 units (0.12 mL) |
| Weeks 9–12 | 200 mcg | 12 units (0.12 mL) |
| Weeks 13–16 | 200 mcg | 12 units (0.12 mL) |
Frequency: Inject once daily subcutaneously. This once-daily schedule balances efficacy with receptor recovery time, avoiding the rapid attenuation seen with frequent dosing[4]. Administering in the evening may capitalize on nocturnal GH rhythms. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Stimulate endogenous growth hormone secretion through ghrelin receptor activation[15].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 100–300 mcg daily with gradual titration; higher doses show dose-dependent responses but may offer limited added benefit with routine use[17].
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated (use within 2–3 weeks for optimal integrity).
Suggested daily titration approach.
- Start: 100 mcg daily (Weeks 1–2); this starting dose provides strong GH pulse while allowing tolerance assessment.
- Mid-level: 150 mcg daily (Weeks 3–4) to enhance GH response if well tolerated.
- Target: 200 mcg daily (Weeks 5–16) for maximal effect in most research scenarios; advanced researchers may optionally increase to 250–300 mcg.
- Frequency: Once per day (subcutaneous); evening administration may align with nocturnal GH rhythms.
- Cycle Length: 8–16 weeks; some attenuation may occur in first 1–2 weeks but response stabilizes with continued dosing[4].
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl or roll until completely dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide potency.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; powder is stable at room temperature for short periods but freezer storage maximizes shelf life[20].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–3 weeks for optimal integrity[20]. For longer storage, consider aliquoting and freezing at −20 °C (−4 °F) with carrier protein; avoid repeated freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
- Always protect from light and heat.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[21][22].
- Clean the vial rubber stopper and skin with alcohol swabs; allow to dry completely.
- Use a fine insulin syringe (typically 29–31 gauge, 0.5-inch needle).
- Pinch an inch of skin fat (abdomen, thigh, or outer upper arm); insert needle at 45° to 90° into subcutaneous tissue[21][22]. (Use 90° angle if ample fatty tissue; 45° for leaner individuals to avoid intramuscular injection.)
- Do not aspirate for subcutaneous injections—aspiration is unnecessary and can cause needless tissue trauma[21][22].
- Inject slowly and steadily; wait a few seconds before withdrawing needle at same angle.
- Apply gentle pressure with swab if needed; do not massage or rub injection site.
- Rotate sites systematically to prevent irritation and lipodystrophy—space injections at least 1 inch apart[21].
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (GHRP-2, 5 mg each):
- 8 weeks ≈ 2 vials
- 12 weeks ≈ 4 vials
- 16 weeks ≈ 5 vials
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
PubMed — Growth hormone response to GHRP-2 (PMC3297037) — Pituitary and hypothalamic mechanisms of GH release stimulation (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Research publication
Pihoker C. et al. (1995) — J Clin Endocrinol Metab — Diagnostic studies with IV and intranasal GHRP-2 in children of short stature (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
Nijland EA. et al. (1998) — Eur J Endocrinol — Five‑day SC GHRP-2 treatment causes response attenuation in young men (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
- 09
Source document
Mountainside Medical — Bacteriostatic Water vs Sterile Water — Multi‑dose vial guidelines; 28‑day use recommendation (opens in a new tab)www.mountainside-medical.com
Back to overview ↑ - 10
Research publication
Usach I. et al. (2019) — Adv Ther (PMC6822791) — Subcutaneous injection of drugs: factors influencing pain and technique (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Public health resource
MedlinePlus — Subcutaneous (SQ) Injections — Site selection, angle guidance, and rotation best practices (opens in a new tab)medlineplus.gov
Back to overview ↑ - 13
Public health resource
NCBI Bookshelf — Best Practices for Injections — Asepsis, preparation, and administration standards (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 15
Research publication
Domest Anim Endocrinol — Effects of GHRP-2 on GH release and growth performance in swine (mechanism and receptor activation) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 16
Research publication
J Clin Endocrinol Metab — Effects of eight months treatment with graded doses of GHRP-2 in GH-deficient children (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 17
Research publication
Endocrine — GH/IGF-1 response to acute and chronic GHRP-2, GHRH 1-44, and their combination in older adults (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 18
Research publication
Am J Men’s Health — Growth hormone secretagogue treatment in hypogonadal men raises serum IGF-1 levels (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 19
Research publication
Sex Med Rev (PMC) — The safety and efficacy of growth hormone secretagogues: comprehensive review (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 22
- 23
Continue exploring
Related topics are not interchangeable compounds or formulations.